Eosinophilic esophagitis is a chronic inflammatory condition of the esophagus caused by a bildup of eosinophils, a type of ...
According to DataM Intelligence, the Orphan Drugs Market Size was USD 223.76 billion in 2023 and is forecasted to soar to USD ...
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
EoE is increasingly diagnosed in Europe, yet for many patients, the biggest hurdle lies beyond treating the inflammation.
As you gather around the table this Thanksgiving to share meals, stories and traditions, consider taking a moment to talk ...
Everyday Health on MSN
Eosinophilic Esophagitis: What to Do if Proton Pump Inhibitors (PPIs) Aren't Helping
If you feel like you’ve hit a treatment wall with proton pump inhibitors (PPIs), here's why your EoE symptoms may still be ...
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...
Background Eosinophilic oesophagitis (EoE) is a chronic allergic disease characterised by oesophageal epithelial remodelling, barrier dysfunction and inflammation. The transcription factor forkhead ...
Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback